Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ARMOUR Residential REIT, Inc. (ARR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ARMOUR Residential REIT, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.07 (market cap $29.60B), while ARMOUR Residential REIT, Inc. trades at $16.73 (market cap $2.07B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 14.3× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ARR | |
|---|---|---|
Market Cap | $29.60B | $2.07B |
Sector | Health | Financials |
52-Week High | $491.22 | $19.12 |
52-Week Low | $205.48 | $14.05 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 17.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
ARMOUR Residential REIT (ARR) trades at $16.74, up 1.18% with neutral technical signals. The REIT shows strong profitability with 97.43% net income margin and attractive valuation at P/E of 3.78 and P/B of 0.91. Recent Q2 2026 earnings beat expectations at $0.72 per share versus $0.69 estimate. The company maintains consistent dividend payments with recent $0.24 distributions. Cash flow trends show operational stability despite significant investing activities.
ARR presents value opportunity with deep discount to book value and high dividend yield, though mixed earnings performance and heavy mortgage-backed securities exposure create volatility risk. Analyst consensus remains cautious with 60% hold rating, reflecting balanced outlook between attractive valuation and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →
